ZIOPHARM Oncology, Inc. (ZIOP)(製薬・医療分野):企業M&A動向

◆英語タイトル:ZIOPHARM Oncology, Inc. (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH24573D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月30日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

ZIOPHARM Oncology, Inc. (ZIOPHARM Oncology) is a biopharmaceutical company. The company discovers and develops cancer therapies. Its products include palifosfamide, IL-12 DNA program, indibulin and darinaparsin. ZIOPHARM Oncology’s indibulin is a tubulin binding agent in phase II clinical trial in metastatic breast cancer; and darinaparsin is a novel organic arsenic molecule synthesized by conjugating dimethylarsenic to glutathione. Its activity includes disruption of mitochondrial function, inhibition of angiogenesis and modified signal transduction, leading to cell cycle arrest and apoptosis. Darinaparsin is active against hematological and solid cancers both in vitro and in vivo. The company partners with Intrexon Corporation. The company was formerly known as EasyWeb, Inc. ZIOPHARM Oncology is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology, Inc. (ZIOP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ziopharm Expands Co-Development Agreement with Intrexon 10
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 11
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 13
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 14
Licensing Agreements 16
Intrexon, Ziopharm Oncology Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 16
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 18
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20
Equity Offering 22
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 27
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million 29
ZIOPHARM Oncology Completes Public Offering For US$48 Million 31
ZIOPHARM Oncology Completes Private Placement Of US$5 Million 33
ZIOPHARM Oncology, Inc. – Key Competitors 35
Key Employees 36
Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Deals By Therapy Area, 2009 to YTD 2015 8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
Ziopharm Expands Co-Development Agreement with Intrexon 10
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 11
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 13
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 14
Intrexon, Ziopharm Oncology Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 16
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 18
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 27
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million 29
ZIOPHARM Oncology Completes Public Offering For US$48 Million 31
ZIOPHARM Oncology Completes Private Placement Of US$5 Million 33
ZIOPHARM Oncology, Inc., Key Competitors 35
ZIOPHARM Oncology, Inc., Key Employees 36

List of Figures
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

★海外企業調査レポート[ZIOPHARM Oncology, Inc. (ZIOP)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Energy Limited (BUL):企業の財務及び戦略的SWOT分析
    Summary Blue Energy Limited (BEL) is an oil and gas company that offers exploration services. The company carries out exploration and production of coal seam gas and conventional oil and gas resources. Its projects include Bowen Basin, Carpentaria Basin, Cooperand Eromanga Basin, Galilee Basin, Mary …
  • BioLight Israeli Life Sciences Ltd (BOLT):企業のM&A・提携動向(医療機器分野)
    Summary BioLight Israeli Life Sciences Ltd (Bio-Light) is an ophthalmic company that concentrates on the discovery, development and commercialization of products and product candidates that address ophthalmic conditions; including glaucoma, dry eye syndrome, or DES, and age-related macular degenerat …
  • California Institute of Technology:企業のM&A・提携動向(医療機器分野)
    Summary California Institute of Technology (Caltech) is a technology research institute that provides research and education services in the areas of mathematics, science and engineering. The institute offers services through academic divisions including biology, chemistry and chemical engineering, …
  • Arla Foods a.m.b.a.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Arla Foods a.m.b.a. Mergers and …
  • Hitachi Kokusai Electronic Inc.:企業の戦略・SWOT・財務分析
    SummaryHitachi Kokusai Electronic Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the comp …
  • Canexus Corporation (CUS):企業のM&A・提携動向(石油・ガス分野)
    Summary Canexus Corporation (Canexus), formerly Canexus Income Fund is chemical company that offers chemical manufacturing and handling services. The company offers sodium chlorate and chlor-alkali products for the pulp and paper and water treatment industries. It offers products such as sodium chlo …
  • Max Life insurance Co. Ltd.:企業の戦略・SWOT・財務分析
    SummaryMax Life insurance Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Incremental Petroleum, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Incremental Petroleum, Ltd. Mer …
  • Novotech (Australia) Pty Limited(製薬・医療分野):企業M&A動向
    Summary Novotech (Australia) Pty Limited (Novotech) is a full service contract research organization (CRO). It offers a wide range of clinical development services. Some of its key services include clinical trials, commercialization, data management, audits, biostatistics, medical writing and regula …
  • PGE Energia Odnawialna S.A.:企業のM&A・提携動向(エネルギー分野)
    Summary PGE Energia Odnawialna S.A. (PGE Energia), a subsidiary of PGE Polska Grupa Energetyczna S.A, is a power company that generates electricity from renewable energy sources, and offers ancillary control services. The company operates various run-of-river and pumped-storage hydro electric power …
  • China Hi-Tech Group Co. Ltd. (600730):企業概要、財務及び戦略的SWOT分析
    Summary China Hi-Tech Group Co. Ltd. (China Hi-Tech) is a trading company. The company conducts real estate development activities that include development of commercial and residential housing, golf courses, lake apartments, and housing distribution business. It provides property leasing, electroni …
  • AVT McCormick Ingredients Pvt. Ltd.:企業の戦略・SWOT・財務分析
    SummaryAVT McCormick Ingredients Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the …
  • Monro Muffler Brake, Inc. (MNRO):企業財務及び戦略的SWOT分析
    Summary Monro Muffler Brake, Inc. (Monro) is an automotive service provider that offers maintenance repair and tire services. The company’s maintenance services include oil change, state inspection, scheduled maintenance, maintenance inspection, fluids service, A/C systems service, and fleet service …
  • Dishman Pharmaceuticals and Chemicals Limited (DISHMAN)(製薬・医療分野):企業M&A動向
    Summary Dishman Pharmaceuticals and Chemicals Limited (Dishman) is a pharmaceutical company. It develops, manufactures and supplies Active Pharmaceutical Ingredients (API). The company offers a portfolio of development, scale-up and manufacturing services. The product portfolio of the company includ …
  • ZTE Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ZTE Corporation Mergers and Acq …
  • Mistras Group, Inc. (MG):企業の財務及び戦略的SWOT分析
    Summary Mistras Group, Inc. (Mistras) is a technology solution company that provides non-destructive testing solutions and instrumentation. The company’s products include acoustic emission, ultrasonic, and vibration and PdM products. It offers acoustic emission products such as AE sensors, AE softwa …
  • Oncodesign SA (ALONC):企業財務及び戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its …
  • Porsolt and Partners Pharmacology:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Porsolt and Partners Pharmacolo …
  • TransAtlantic Petroleum Ltd. (TAT):企業のM&A・提携動向(石油・ガス分野)
    Summary TransAtlantic Petroleum Ltd. (TransAtlantic), formerly TransAtlantic Petroleum Corp., is an oil and gas company. It acquires, explores for, develops and produces oil and natural gas. The company focuses on developing onshore and offshore properties in countries that are underexplored and net …
  • Solera Holdings, Inc. (SLH):企業の財務及び戦略的SWOT分析
    Summary Solera Holdings, Inc. (Solera) is a technology service company that provides software and related services to automobile insurance claims processing industry. The company’s products are used in the areas of auto repair estimation, recycling and salvage vehicle history, and insurance re-under …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆